Neoplasms by Histologic Type
A collective term for the various histological types of NEOPLASMS. It is more likely to be used by searchers than by indexers and catalogers.
Subtype terms (14)
More specific conditions that are subtypes of Neoplasms by Histologic Type in the MeSH hierarchy.
- Histiocytic Disorders, Malignant
1 drug approved
- Leukemia
598 drugs (276 approved, 322 experimental)
- Lymphoma
1111 drugs (436 approved, 675 experimental)
- Neoplasm, Lymphatic Tissue
- Neoplasms, Complex and Mixed
- Neoplasms, Connective and Soft Tissue
16 drugs (12 approved, 4 experimental)
- Neoplasms, Germ Cell and Embryonal
148 drugs (95 approved, 53 experimental)
- Neoplasms, Glandular and Epithelial
31 drugs (19 approved, 12 experimental)
- Neoplasms, Gonadal Tissue
- Neoplasms, Nerve Tissue
21 drugs (12 approved, 9 experimental)
- Neoplasms, Plasma Cell
54 drugs (39 approved, 15 experimental)
- Neoplasms, Vascular Tissue
- Nevi and Melanomas
- Odontogenic Tumors
Drugs by status
Phase 4 trials (2)
Phase 3 trials (15)
Phase 2 trials (30)
- anlotinib
- olaparib
- lenalidomide
- diphenhydramine
- paclitaxel
- niraparib
- osimertinib
- acetaminophen
- sunitinib
- Isatuximab
- cyclophosphamide
- bevacizumab
- bortezomib
- cd30-car t cells
- fludarabine
- varlilumab
- rituximab
- oxaliplatin
- pomalidomide
- ranitidine
- dexamethasone
- lisocabtagene maraleucel
- cynk-001
- im19 car-t cells
- penpulimab
- blu-701
- blu-945
- the-630
- blu-451
- tqb2450
Phase 1 trials (21)
Other trials (2)
Organizations
Organization Involved with Phase 3 Indications (3)
Organization Involved with Phase 2 Indications (11)
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (4)